Sonam Verma

Dr. Sonam Verma


Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 July 2020 in American Journal of Reproductive Immunology
Verified
Journal Article
Closed access
PDF file
SVSonam Verma
Sonam Verma
ECEbony B. Carter
Ebony B. Carter
IMIndira U. Mysorekar
Indira U. Mysorekar

1 May 2021 in Med
Verified
Journal Article
Closed access
SVSonam Verma
Sonam Verma
CJChetanchandra S. Joshi
Chetanchandra S. Joshi
RSRachel B. Silverstein
Rachel B. Silverstein
MHMai He
Mai He
ECEbony B. Carter
Ebony B. Carter
IMIndira U. Mysorekar
Indira U. Mysorekar

1 January 2018 in Taiwan Journal of Ophthalmology
Verified
Journal Article
Open access
PDF file
RKRavindra Kumar
Ravindra Kumar
NNNitin Nema
Nitin Nema
SVSonam Verma
Sonam Verma
PURPOSE: Thromboembolic phenomenon is one of the causes of retinal vein occlusion (RVO) which is in fact a multifactorial disease. Therefore, we aimed to study methylenetetrahydrofolate reductase gene polymorphism (MTHFR C677T) and factor V Leiden as genetic risk factors of RVO. MATERIALS AND METHODS: A total of 50 (19 males and 31 females) cases of RVO were compared with 50 age- and sex-matched (21 males and 29 females) controls. Complete ocular examination was done for all samples. The diagnosis of RVO was made clinically; however, fundus fluorescein angiography and optical coherence tomography were performed when needed. Serum homocysteine levels were estimated by automatic chemiluminescence analyzer, whereas MTHFR C677T and factor V Leiden mutations were detected by polymerase chain reaction–restriction fragment length polymorphism method. RESULTS: The mean age of RVO cases and controls was 54.62 ± 13.92 years and 58.72 ± 11.20 years, respectively. 48.3% of cases and 51.7% of controls were diabetic. 65.3% of cases were hypertensive proving hypertension as a strong risk factor (P = 0.003) of RVO. Serum homocysteine was also found significantly high (P = 0.025) with mean values of 19.98 ± 9.03 μmol/L and 16.98 ± 8.29 μmol/L in cases and controls, respectively. The MTHFR genotype (CT) was found in 83.3% patients of central RVO group and 78.6% cases of branch RVO group that was significantly associated with high serum homocysteine levels. Factor V Leiden mutation was absent in all individuals. CONCLUSION: Hyperhomocysteinemia is an important risk factor for RVO, especially in patients with MTHFR C677T gene polymorphism.

8 August 2026 in Neuro-Oncology
Verified
Journal Article
Closed access
AKAshwani Kesarwani
Ashwani Kesarwani
AGAmber Griffith
Amber Griffith
SVSonam Verma
Sonam Verma
THTong Hu
Tong Hu
FSFei Shu
Fei Shu
MCMilan G Chheda
Milan G Chheda
Background: The glioblastoma (GBM) immunosuppressive tumor microenvironment is a clinical challenge. Oncolytic Zika virus (ZIKV) has emerged as a promising therapy, targeting treatment-resistant glioma stem cells, stimulating CD8+ T-cell-mediated immunity and extends survival in preclinical models but myeloid cell-driven immunosuppression persists. An antagonist of Siglec-15, a myeloid immune checkpoint molecule, is in a phase II trial for non-small cell lung cancer, but its role in CNS malignancies remains unclear. Methods: We evaluated Siglec-15 expression in human GBM samples using flow cytometry, mass cytometry, and immunofluorescence, as well as a public database. Using syngeneic glioma models, we tested a blocking antibody against Siglec-15, and Siglec-15 knockout mice, alongside ZIKV and anti-PD-1 therapies. We performed survival studies and analyzed immune responses, T-cell proliferation and phagocytosis, and tumor rechallenge. Results: Siglec-15 was expressed by human GBM myeloid (16%-22%) and tumor (18%-19%) cells, and higher expression was associated with shorter survival. In CT2A-bearing mice, ZIKV + anti-Siglec-15 increased long-term survival to 60% (vs 40% with ZIKV alone), rising to 83% with anti-PD-1 treatment. Triple therapy in SB28 bearing mice yielded 76% long-term survivor rate with 1.7-fold higher CD8+ T-cell activation. Rechallenged mice showed 11-fold expansion of brain resident/effector memory CD8+ T cells and 80% survival. Siglec-15 loss on myeloid cells enhanced phagocytosis (CT2A: 25%; SB28: 7%) and T-cell responses (activation: 81%; proliferation: 86.8%). Conclusion: Targeting Siglec-15, combined with PD-1 blockade and ZIKV overcomes myeloid immunosuppression and enhances T-cell activation in GBM, promoting durable antitumor immunity. These findings support further investigation of this combination therapy.

15 May 2003
Verified
Book Chapter
Closed access
PDF file
KBKathleen Berry
Kathleen Berry
SVSonam Verma
Sonam Verma
DMDavid Moore
David Moore

31 August 2023 in International Journal for Research in Applied Science and Engineering Technology
Verified
Journal Article
Open access
NRNeha Rani
Neha Rani
SVSonam Verma
Sonam Verma
KDKarishma Das
Karishma Das
PPPalas Pramanick
Palas Pramanick
KCKomal Chauhan
Komal Chauhan